Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma

<p>Supplementary Figure 5: Single-cell RNA Sequencing and IHC examination of ALK in human neural development and immature neural cells. A. 2D representation of human brain cell subtypes (48 samples) during cortex development using a single cell RNA-seq atlas (cortex-dev.cells.ucsc.edu) shows t...

Saved in:

書目詳細資料
主要作者:	Anne-Florence Blandin (15056366) (author)
其他作者:	Ross Giglio (15056369) (author), Maya Srikanth Graham (15056372) (author), Guadalupe Garcia (15056375) (author), Seth Malinowski (15056378) (author), Jared K. Woods (15056381) (author), Shakti Ramkissoon (15056384) (author), Lori Ramkissoon (15056387) (author), Frank Dubois (15056390) (author), Kathleen Schoolcraft (15056393) (author), Jessica Tsai (15056396) (author), Dayle Wang (15056399) (author), Robert Jones (15056402) (author), Jayne Vogelzang (15056405) (author), Kristine Pelton (15056408) (author), Sarah Becker (15056411) (author), Fiona Watkinson (15056414) (author), Claire Sinai (15056417) (author), Elizabeth F. Cohen (15056420) (author), Matthew A. Booker (15056423) (author), Michael Y. Tolstorukov (15056426) (author), Veerle Haemels (15056429) (author), Liliana Goumnerova (15056432) (author), Karen Wright (15056435) (author), Mark Kieran (15056438) (author), Katie Fehnel (15056441) (author), David Reardon (15056444) (author), Arnault Tauziede-Espariat (15056447) (author), Rishi Lulla (15056450) (author), Benjamin Carcamo (15056453) (author), Stanley Chaleff (15056456) (author), Alain Charest (15056459) (author), Frederik De Smet (14957559) (author), Azra H. Ligon (15056462) (author), Adrian Dubuc (15056465) (author), Melanie Pages (15056468) (author), Pascale Varlet (15056471) (author), Patrick Y. Wen (15056474) (author), Brian M. Alexander (15019467) (author), Susan Chi (15056477) (author), Sanda Alexandrescu (9122099) (author), Ralf Kittler (14864988) (author), Robert Bachoo (15056480) (author), Pratiti Bandopadhayay (15056483) (author), Rameen Beroukhim (15056486) (author), Keith L. Ligon (14958845) (author)
出版:	2025
主題:	Cancer Cancer Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Methods and Technology Biomarkers Cell Signaling Receptors CNS Cancers Gliomas, Glioblastomas Drug Targets Protein kinase & phosphatase drug targets Oncogenes & Tumor Suppressors Oncogenes Pediatric Cancers Preclinical Models Xenograft models
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
由: Ana Vujovic (15207479)
出版: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
由: Smruthy Sivakumar (15053536)
出版: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
由: Feng Wang (44414)
出版: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
由: Feng Wang (44414)
出版: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
由: Feng Wang (44414)
出版: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
由: Feng Wang (44414)
出版: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
由: Nicholas T. Younger (14956251)
出版: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
由: Nicholas T. Younger (14956251)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_549kcpdi6l90nnrnpuorgr1g0q